e-learning
resources
Munich 2006
Sunday 03.09.2006
Virus-induced respiratory tract infection
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Simultaneous use of probiotics and vaccines for prevention of pneumonia and respiratory infections in servicemen
S. D. Zhogolev, P. I. Ogarkov, K. D. Jogolev, V. P. Dobrisa, L. N. Petrov, T. S. Sologub (St Petersburg, Russian Federation)
Source:
Annual Congress 2006 - Virus-induced respiratory tract infection
Session:
Virus-induced respiratory tract infection
Session type:
Oral Presentation
Number:
965
Disease area:
Respiratory infections
Abstract
Efficiency of simultaneous use of influenza and pneumococcal vaccines and probiotic Vitaflor (developed on the basis of two Lactobacillus species) to prevent pneumonia and ARD was studied in 3 groups of recruits.
The group 1 (n=145) was given Vitaflor as a sour-milk product (a cup t.i.d.) and as nasal drops for the first 10 days after arrival in the unit. Five drops of Vitaflor (water solution) were used in each nasal meatus t.i.d. At the 3
d
-5
th
day after beginning of Vitaflor prophylaxis the influenza vaccine was used.
The group 2 (n=114) received Vitaflor (the same scheme) as well but simultaneously was vaccinated with Grippol and Pneumo 23 (pneumococcal vaccine).
The group 3 (n=171) served as a control, and was vaccinated only with Grippol.
After vaccination and Vitaflor course a bacteriologic examination of all three groups was carried out. It was established that a number of pneumococcus and haemophilic bacillus was significantly lower than in the control group.
Within five-month follow-up the incidence of pneumonia in groups 1 and 2 was 1.8 and 2.9 times lower than in the control group. The incidence of ARD in groups 1 and 2 was 2.9 and 4.1 times lower than in the control group (p<0.001).
Persons who had received a course of Vitaflor had a better specific immune response after pneumococcal and influenza vaccination and
an improvement of the indices of nonspecific body resistance.
Thus, the most effective
scheme of prophylaxis of pneumonia and ARD among used means was a combined vaccination with influenza and pneumococcal vaccines conducted on the background of 10 days course of Vitaflor.
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. D. Zhogolev, P. I. Ogarkov, K. D. Jogolev, V. P. Dobrisa, L. N. Petrov, T. S. Sologub (St Petersburg, Russian Federation). Simultaneous use of probiotics and vaccines for prevention of pneumonia and respiratory infections in servicemen. Eur Respir J 2006; 28: Suppl. 50, 965
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Promising prophylactic means and methods for prevention of community-acquired pneumonia and respiratory infections among servicemen in Russia
Source: Eur Respir J 2006; 28: Suppl. 50, 350s
Year: 2006
Impact of appropriate diagnostics on the management of respiratory tract infections
Source: Value-Dx event 2021: Community-acquired respiratory tract infections: where do we stand in 2021, ECCMID 2021
Year: 2021
Current treatments for respiratory infections in children
Source: Annual Congress 2005 - PG5 - Paediatrics: respiratory infections in children
Year: 2005
Use of polyvalent antigenic complex for prophylaxis of community-acquired pneumonia and respiratory infections among recruits of Russia
Source: Annual Congress 2006 - Epidemiological aspects of lung tumors and infections including tuberculosis
Year: 2006
Efficiency of the specific and nonspecific means for prevention of pneumonia and respiratory infections in recruits
Source: Eur Respir J 2005; 26: Suppl. 49, 143s
Year: 2005
Potential impact and relevance of diagnostics in the management of respiratory tract infections: from COVID to hospital-acquired pneumonia
Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections
Year: 2021
Effectiveness of 23-valent pneumococcal polysaccharide vaccine in preventing lower respiratory tract infections complicating chronic respiratory failure
Source: Eur Respir J 2006; 28: Suppl. 50, 576s
Year: 2006
Prevention of paediatric respiratory tract infections: emphasis on the role of OM-85
Source: Eur Respir Rev 2005; 14: 74-77
Year: 2005
Economic aspects of enhanced testing strategies for respiratory diseases
Source: Value-Dx event 2021: Community-acquired respiratory tract infections: where do we stand in 2021, ECCMID 2021
Year: 2021
Effect of COVID19 preventive measures on respiratory infections and symptoms in children
Source: Virtual Congress 2021 – Causes and consequences of paediatric respiratory diseases
Year: 2021
Update on preventing and managing hospital-acquired and ventilatory-associated pneumonia
Source: International Congress 2019 – State of the art session: Respiratory infections
Year: 2019
Prevention of nosocomial infections in acute respiratory failure patients
Source: Eur Respir J 2003; 22: 72S-76S
Year: 2003
Update on therapeutic strategies in community-acquired pneumonia
Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice
Year: 2017
Antibiotics and new guidelines for the treatment of lower respiratory tract infections
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=175
Year: 2004
The efficacy of antiviral therapy of acute respiratory infections in paediatric practice
Source: International Congress 2017 – New insights into paediatric respiratory infections
Year: 2017
Are antimicrobials still the future of respiratory infection therapy?
Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections
Year: 2021
Lower respiratory tract infections: when are antibiotics mandatory?
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=146
Year: 2004
Should pneumococcal vaccines be used to prevent LRTI?
Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new?
Year: 2009
Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines
Source: Eur Respir J 2011; 37: 112-118
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept